Wednesday, September 12, 2018, Diffusion Pharmaceuticals (DFFN) closed the session up 13.21% in the market after the company announced that the FDA has approved an innovative clinical trial design. Instead of taking place in the clinic, the trial will take place in ambulances in cities, suburbs and rural areas.
The treatment, the TSC molecule, is being developed as a potential therapeutic to treat acute stroke, a market that comes with massive potential.
On the same note, the company's financial stability is relatively strong and will likely take it through more than a year, through which time, multiple catalysts are likely.
Although there are always risks to consider when making any investment, I believe that the potential rewards far outweigh the risks in this scenario.
Diffusion Pharmaceuticals Gets The Green Light On TSC In-Ambulance Studies
Diffusion Pharmaceuticals has received the green light from the United States Food and Drug Administration (FDA) to move forward with a unique clinical trial. The PHAST-TSC (Pre-Hospital Ambulance Stroke Trial-TSC) has been approved by the FDA to begin enrolling patients.
During the Phase 2 clinical trial, the company will assess its lead candidate, trans sodium concentrate (TSC) for the treatment of acute stroke. Interestingly, this Phase 2 trial will not be taking place in the clinic. Because the treatment is expected to be most effective when delivered to the patients as quickly as possible, the trial will take place in the ambulance that picks participating patients up when they experience a stroke. This is nothing like any other trial design seen in the pa